Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD0240 |
| Synonyms | |
| Therapy Description |
AZD0240 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting KRAS G12D in the context of HLA-A*11:01, which potentially induces cytokine production and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3478). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD0240 | AZD 0240|AZD-0240 | AZD0240 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting KRAS G12D in the context of HLA-A*11:01, which potentially induces cytokine production and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3478). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06218914 | Phase I | AZD0240 NT-112 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Recruiting | USA | 0 |